权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

The role of PARP inhibitor target engagement in breast cancer

PARP 抑制剂靶点参与在乳腺癌中的作用

基本信息

批准号：
9752234
负责人：
John Dubach
金额：
$ 24.9万
依托单位：
MASSACHUSETTS GENERAL HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-09-01 至 2021-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9752234
关键词：
Antineoplastic Agents Area Biological Biology Breast Cancer Cell Breast Cancer Model Breast Cancer Treatment Cell Culture Techniques Cells Clinical Clinical Trials Complex DNA Double Strand Break Data Development Doctor of Philosophy Drug Targeting Failure Fluorescence Anisotropy Fluorescence Polarization General Hospitals Goals Heterogeneity High Prevalence Image In Vitro Label Light Malignant Neoplasms Massachusetts Measurement Measures Mentors Mentorship Methods Microscopy Modeling Mus Mutate Mutation Outcomes Research Pathway interactions Pharmaceutical Preparations Phase Polarization Microscopy Poly(ADP-ribose) Polymerases Proteins Research Personnel Resolution Role Systems Biology Techniques Testing Therapeutic Treatment Failure Work analog biological systems cancer cell cancer therapy cellular targeting clinically relevant drug distribution experience experimental study fluorescence imaging imaging approach imaging system in vivo in vivo Model inhibitor/antagonist insight intravital fluorescence microscopy malignant breast neoplasm medical schools mouse model mutant novel novel imaging technique off-label drug orthotopic breast cancer public health relevance response sensor success targeted imaging temporal measurement treatment response triple-negative invasive breast carcinoma tumor

项目摘要

DESCRIPTION (provided by applicant): The broad goal of this proposal is to develop new imaging approaches to understand the complex biology of drug activity in vivo. Specifically, I will develop and optimize a fluorescence polarization microscopy approach to image target engagement of cancer drugs at cellular resolution in mouse tumor models. This technique, entitled competition multiphoton fluorescence anisotropy microscopy (compMFAM), enables imaging of unlabeled drug target engagement through competition with fluorescently labeled drug of the same target. Measuring target engagement provides insight into the mechanism of treatment failure when a drug proves ineffective. These data can be used to determine if failure arises from inefficient drug distribution or inability of the target to effect the cell. The candidte, J. Matt Dubach, PhD, has extensive experience in novel sensor development for fluorescent imaging of difficult to measure targets. The long term goal of the candidate is to develop novel imaging approaches to better understand cancer at the cellular level in biological systems. The proposed work will be conducted at the Center for Systems Biology at Massachusetts General Hospital and Harvard Medical School under the mentorship of Ralph Weissleder, MD, PhD and Tim Mitchison, PhD. The mentorship team will assist in the candidate's development during the mentored phase of the pathway to independence and help the candidate transition into an independent researcher. The specific aims of this proposal focus on two areas: technological development of the imaging system; and biological applications to measure the role of PARP target engagement in treatment of breast cancer through mouse models. There are several promising PARP inhibitors currently in clinical trials for a variety of cancers. Largely due to the high prevalence of BRCA mutations in breast cancer, PARP inhibitors are currently be explored as single agent treatment in triple negative breast cancer. Preliminary feasibility experiments demonstrate that this is a valid approach to quantitatively measure target engagement of drug in vivo. There are two specific aims in this proposal: 1) Validate compMFAM technique to measure cellular level target engagement; and 2) Determine how target engagement governs successful PARP inhibitor treatment. Aim 1 will be accomplished under the mentorship team, while Aim 2 will be performed as an independent investigator. Successful completion of this proposal would provide insight into how PARP target engagement governs cellular response in successful and unsuccessful treatment while providing a generalizable approach to study target engagement of nearly any inhibitor drug class.

描述（由申请人提供）：本提案的总体目标是开发新的成像方法，以了解体内药物活性的复杂生物学。具体来说，我会